

Table 6. Baseline demographic characteristics of patients that were excluded in the primary analysis


	Xpert Group
	(N=79)
Mean age (SD), years	33·2±10·9
Female, % (n)	55·7 (44)
HIV status, % (n)	
Positive	81·0 (64)
Negative	19·0 (15)
ART ^a status, % (n) ^b	
On ART	51·6 (33)
Not on ART	48·4 (31)

^aART: anti-retroviral therapy


^bonly for known HIV positive patients

Table 7. Sensitivity analyses of treatment outcomes of patients in the two study groups

Treatment outcome, %, (n)	Conventional Group (n=813)	Xpert Group (n=187)	p-value
Treatment success	54·0 (439)	50·8 (95)	0·465
Treatment completed	19·6 (159)	10·2 (19)	0·002
Cure	34·4 (280)	40·6 (76)	0·127
Default	28·3 (230)	18·2 (34)	0·004
Treatment failure	3·6 (29)	4·3 (8)	0·667
Death	13·9 (113)	19·2 (36)	0·069
Transferred out	0·2 (2)	1·1 (2)	0·161
Outcome unknown	0	6·4 (12)	-



A



B

Figure 2. Comparison between the scores of two chest radiograph readers with a Bland-Altman diagram for Xpert MTB/RIF assay (A) and Conventional (B) groups